Clinicopathological and prognostic value of necroptosis-associated lncRNA model in patients with kidney renal clear cell carcinoma was written by Gu, Jun;He, Zexi;Huang, Yinglong;Luan, Ting;Chen, Zhenjie;Wang, Jiansong;Ding, Mingxia. And the article was included in Disease Markers in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:
Necroptosis, a recently identified type of programmed necrotic cell death, is closely related to the tumorigenesis and development of cancer. However, it remains unclear whether necroptosis-associated long noncoding RNAs (lncRNAs) can be used to predict the prognosis of kidney renal clear cell carcinoma (KIRC). This work was designed to probe the possible prognostic worth of necroptosis-associated lncRNAs along with their impact on the tumor microenvironment (TME) in KIRC. The Cancer Genome Atlas (TCGA) database was used to extract KIRC gene expression and clinicopathol. data. Pearson correlation anal. was used to evaluate necroptosis-associated lncRNAs against 159 known necroptosis-associated genes. To define mol. subtypes, researchers used univariate Cox regression anal. and consensus clustering, as well as clin. significance, TME, and tumor immune cells in each mol. subtype. We develop the necroptosis-associated lncRNA prognostic model using univariate Cox regression anal. and least absolute shrinkage and selection operator (LASSO) regression anal. Patients were divided into high- and low-risk groups according to prognostic model. Moreover, comprehensive analyses, including prognostic value, gene set enrichment anal. (GSEA), immune infiltration, and immune checkpoint gene expression, were performed between the two risk groups. Finally, anticancer drug sensitivity analyses were employed for assessing associations for necroptosis-associated lncRNA expression profile and anticancer drug chemosensitivity. Through univariate anal., sixty-nine necroptosis-associated lncRNAs were found to have a significant relationship with KIRC prognosis. Two mol. clusters were identified, and significant differences were found with respect to clinicopathol. features and prognosis. The segregation of patients into two risk groups was done by the constructed necroptosis-associated lncRNA model. The survival prognosis, clin. features, degree of immune cell infiltration, and expression of immune checkpoint genes of high-risk and low-risk groups were all shown to vary. Our study identified a model of necroptosis-associated lncRNA signature and revealed its prognostic role in KIRC. It is expected to provide a reference for the screening of KIRC prognostic markers and the evaluation of immune response. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Reference of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem